Human Anti-ERBB3 Recombinant Antibody (clone A5) (CAT#: HPAB-1139-FY)

Figure 1 Binding activity of A5 and F4 anti-ERBB3 IgGs.

Equilibrium binding of A5 and F4 IgGs to purified ERBB3 extracellular domains was quantified in an ELISA format by incubating 4 fold-serial dilutions of IgG (1333–0.02 nM) and 0 nM control with immobilized ERBB3, and bound antibody was detected with HRP-conjugated anti-human Fc secondary antibody.

D’Souza, J. W., Reddy, S., Goldsmith, L. E., Shchaveleva, I., Marks, J. D., Litwin, S., & Robinson, M. K. (2014). Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PloS one, 9(11), e112376.

Figure 2 Binding activity of A5 and F4 anti-ERBB3 IgGs.

Increasing amounts (0, 0.5, 2, 5 m g) of A5 and F4 IgG were incubated with BT-474 cells (250,000 cells/assay) and binding was detected by flow cytometry with a FITC-conjugated anti-human Fc secondary antibody.

D’Souza, J. W., Reddy, S., Goldsmith, L. E., Shchaveleva, I., Marks, J. D., Litwin, S., & Robinson, M. K. (2014). Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PloS one, 9(11), e112376.

Figure 3 Combining A5 and F4 IgGs improves growth inhibition of ERBB3-positive cell lines and synergizes with ERBB-targeted agents.

Individual, pairwise, and triple combinations of A5, F4 and either trastuzumab or erlotinib (as appropriate) were serially diluted (2-fold dilution scheme) and incubated with the ERBB2-positive cell lines, BT-474, SK-BR-3, NCI-N87, and EGFR-positive cell line ACHN, as noted.

D’Souza, J. W., Reddy, S., Goldsmith, L. E., Shchaveleva, I., Marks, J. D., Litwin, S., & Robinson, M. K. (2014). Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PloS one, 9(11), e112376.